Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
| Revenue (TTM) | $85.53M |
| Gross Profit (TTM) | $49.97M |
| EBITDA | $7.82M |
| Operating Margin | -4.52% |
| Return on Equity | -78.60% |
| Return on Assets | 1.73% |
| Revenue/Share (TTM) | $19.20 |
| Book Value | $2.23 |
| Price-to-Book | 2.74 |
| Price-to-Sales (TTM) | 0.31 |
| EV/Revenue | 0.754 |
| EV/EBITDA | 44.40 |
| Quarterly Earnings Growth (YoY) | -80.30% |
| Quarterly Revenue Growth (YoY) | -4.70% |
| Shares Outstanding | $4.51M |
| Float | $3.51M |
| % Insiders | 9.48% |
| % Institutions | 41.46% |
Volatility is currently contracting
HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HBIO and any ticker you trade — then tracks every position and per-strategy win rate.
